Gout Therapeutics Market Analysis by Product Type (NSAIDs, Corticosteroids, Colchicine, Preventive Therapies) and Segment Forecasts To 2022
Global gout therapeutics market is estimated to be an attractive market, which is driven by new drug developments in the pharmaceutical industry and availability of the effective treatment options used as preventive therapies for Gout. Factors such as increasing geriatric base, increasing healthcare expenditure, growing awareness, and rising life expectancy is leading to growth of gout therapeutic market. According to the (Centers for Disease Control and Prevention) CDC, the prevalence of gout was 8.3 million individuals among U.S. adults in 2007–2008 which shows prevalence rate of 3.9%.
The demand for gout therapeutics is
expected to increase because of the increasing incidences men and women facing gout. The prevalence of gout among men was 6.1 million (5.9%), and the prevalence among women was 2.2 million (2.0%) in 2007-2008. Irregularity in diet, presence of other diseased conditions such as diabetes or kidney diseases and other medications are the factors anticipated to increase the dependence on the market.